Looking at this filing, I need to identify the substantive financial content. The filing text provided is primarily the cover page, table of contents, and forward-looking statements boilerplate. There are no financial figures, revenue numbers, or substantive operational disclosures in the extracted text. However, I do have some company-specific facts: the share count as of October 31, 2026 (145,004,521 shares), the company identity (Natera, Inc.), the ticker (NTRA on Nasdaq Global Select Market), the filing period (quarter ended September 30, 2026), product names (Signatera, Panorama, Horizon, Foresight Diagnostics acquisition reference), and the filing date. I'll work with what is confirmed in the source text.

Natera, Inc. (NASDAQ:NTRA) filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the Securities and Exchange Commission on November 5, 2026, disclosing 145,004,521 shares of common stock outstanding as of October 31, 2026.

Key Highlights

  • Shares outstanding: As of October 31, 2026, Natera reported 145,004,521 shares of common stock outstanding, par value $0.0001 per share.
  • Large accelerated filer: The company indicated it qualifies as a large accelerated filer under Rule 12b-2 of the Exchange Act.
  • Key products named: The filing identifies Signatera, Panorama, and Horizon as sources from which "a significant portion" of revenues are expected to be derived for the foreseeable future.
  • Acquisition reference: The filing references Natera's integration of Foresight Diagnostics, Inc. as part of its strategic operations.
  • Headquarters: The company is headquartered at 13011 McCallen Pass, Building A Suite 100, Austin, TX 78753.

Natera's Third-Quarter 2026 Quarterly Report: Company and Filing Details

Natera, Inc., a Delaware-incorporated life sciences company listed on the Nasdaq Global Select Market under the ticker NTRA, submitted its Form 10-Q for the quarterly period ended September 30, 2026, to the SEC on November 5, 2026. According to the filing, the company operates in the genetic testing sector, offering products including Signatera, Panorama, and Horizon, which the registrant disclosed it expects to remain significant revenue contributors for the foreseeable future.

The filing states that as of October 31, 2026, 145,004,521 shares of common stock with a par value of $0.0001 per share were outstanding. Natera confirmed it has filed all required reports with the SEC during the preceding 12 months and has submitted all required Interactive Data Files electronically. The registrant indicated it is not a shell company and does not qualify as a smaller reporting company or emerging growth company.

The quarterly report covers financial statements including condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025, condensed consolidated statements of operations for the three and nine months ended September 30, 2026 and 2025, and related cash flow statements, according to the table of contents included in the filing. The filing also references the company's integration of Foresight Diagnostics, Inc. as part of its ongoing strategic activities. The forward-looking statements contained in the report are described by Natera as subject to known and unknown risks and uncertainties, as outlined in the company's Risk Factors disclosures.

What Was Disclosed

Natera, Inc. filed a Form 10-Q for the quarter ended September 30, 2026, reporting 145,004,521 shares outstanding as of October 31, 2026, confirming its large accelerated filer status, and identifying Signatera, Panorama, and Horizon as principal revenue-generating products.